Skip to content

Study · Observational study · n = 333 · 2024

9 results

PIONEER REAL UK: A Multi-Centre, Prospective, Real-World Study of Once-Daily Oral Semaglutide Use in Adults with Type 2 Diabetes.

Saravanan P, Bell H, Braae UC, Collins E, Deinega A, Dhatariya K, Machell A, Trent A, Strzelecka A

Advances in therapy24 Sept 2024Cited by 9 (Europe PMC)

PMID39316289 (opens in a new tab)PMCIDPMC11480173 (opens in a new tab)DOI10.1007/s12325-024-02973-z (opens in a new tab)PepBankPUB-39316289
Read at sourcePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes in UK routine care, oral semaglutide reduced HbA1c by an estimated 1.1 percentage points from baseline to end of study.

    In plain wordsIn adults with type 2 diabetes in routine UK care, oral semaglutide lowered HbA1c compared with the start of treatment.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c change from baseline to end of study
    Study

    n = 333

    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · oral · 34-44 weeksAs given in this study (human).

    Measurements

    HbA1c change
    −1.1 %-points
    end of study

    Source sentences

    Summary
    People treated with oral semaglutide experienced significantly reduced HbA1C by an estimated change of - 1.1%-points (95% CI - 1.27 to - 0.96; P < 0.0001) or - 12.2 mmol/mol (CI - 13.87 to - 10.47; P < 0.0001).
    3 context sentences
    Summary · context
    The primary endpoint was change in glycated haemoglobin (HbA1C) from baseline to end of study (EOS).
    Summary · context
    The multi-centre, prospective and non-interventional single-arm study enrolled 333 participants and followed them for 34-44 weeks.
    Summary · context
    Participants were treated as part of routine clinical practice and had not been previously treated with injectable glucose-lowering medication.
  2. 02HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes in UK routine care, oral semaglutide reduced body weight by an estimated 4.8 kg from baseline to end of study.

    In plain wordsIn adults with type 2 diabetes in routine UK care, body weight fell by about 4.8 kg after starting oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight change from baseline to end of study
    Study

    n = 333

    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · oral · 34-44 weeksAs given in this study (human).

    Measurements

    Body weight change
    −4.8 kg
    end of study

    Source sentences

    Summary
    Estimated change in body weight was - 4.8 kg (CI - 5.47 to - 4.12; P < 0.0001).
    3 context sentences
    Summary · context
    Secondary endpoints included change in body weight, proportion of participants with HbA1C 1C reduction and body weight reduction of ≥ 3% or ≥ 5% at EOS.
    Summary · context
    The multi-centre, prospective and non-interventional single-arm study enrolled 333 participants and followed them for 34-44 weeks.
    Summary · context
    Participants were treated as part of routine clinical practice and had not been previously treated with injectable glucose-lowering medication.
  3. 03HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes in UK routine care, 46.3% of participants on oral semaglutide had HbA1c below 7% at end of study.

    In plain wordsIn adults with type 2 diabetes in routine UK care, 46.3% reached HbA1c below 7% on oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    Not applicableHbA1c below 7% at end of study
    Study

    n = 333

    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · oral · 34-44 weeksAs given in this study (human).

    Measurements

    Participants with HbA1c <7%
    46.3%
    end of study

    Source sentences

    Summary
    At EOS, an HbA1C level < 7% (53 mmol/mol) was recorded in 46.3% of participants.
    2 context sentences
    Summary · context
    The multi-centre, prospective and non-interventional single-arm study enrolled 333 participants and followed them for 34-44 weeks.
    Summary · context
    Participants were treated as part of routine clinical practice and had not been previously treated with injectable glucose-lowering medication.
  4. 04HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes in UK routine care, 36.4% of participants on oral semaglutide had an HbA1c reduction of at least 1%-point with a body weight reduction of at least 3%.

    In plain wordsIn routine UK care, 36.4% of adults with type 2 diabetes had a clear HbA1c fall and at least 3% weight loss on oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    Not applicableHbA1c reduction of 1%-point or more with body weight reduction of 3% or more
    Study

    n = 333

    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · oral · 34-44 weeksAs given in this study (human).

    Measurements

    Participants with HbA1c reduction and weight loss >=3%
    36.4%
    end of study

    Source sentences

    Summary
    A ≥ 1%-point reduction in HbA1C combined with a ≥ 3% reduction in body weight was observed in 36.4% of participants, and 27.1% had a ≥ 1%-point reduction in HbA1C and a ≥ 5% body weight reduction.
    2 context sentences
    Summary · context
    The multi-centre, prospective and non-interventional single-arm study enrolled 333 participants and followed them for 34-44 weeks.
    Summary · context
    Participants were treated as part of routine clinical practice and had not been previously treated with injectable glucose-lowering medication.
  5. 05HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes in UK routine care, 27.1% of participants on oral semaglutide had an HbA1c reduction of at least 1%-point with a body weight reduction of at least 5%.

    In plain wordsIn routine UK care, 27.1% of adults with type 2 diabetes had a clear HbA1c fall and at least 5% weight loss on oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    Not applicableHbA1c reduction of 1%-point or more with body weight reduction of 5% or more
    Study

    n = 333

    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · oral · 34-44 weeksAs given in this study (human).

    Measurements

    Participants with HbA1c reduction and weight loss >=5%
    27.1%
    end of study

    Source sentences

    Summary
    A ≥ 1%-point reduction in HbA1C combined with a ≥ 3% reduction in body weight was observed in 36.4% of participants, and 27.1% had a ≥ 1%-point reduction in HbA1C and a ≥ 5% body weight reduction.
    2 context sentences
    Summary · context
    The multi-centre, prospective and non-interventional single-arm study enrolled 333 participants and followed them for 34-44 weeks.
    Summary · context
    Participants were treated as part of routine clinical practice and had not been previously treated with injectable glucose-lowering medication.
  6. 06HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes in UK routine care, treatment satisfaction improved significantly during oral semaglutide treatment.

    In plain wordsIn adults with type 2 diabetes in routine UK care, people were more satisfied with their treatment while on oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    IncreaseTreatment satisfaction (DTSQ)
    Study

    n = 333

    Outcome group
    Patient-reported outcomes · Whole body
    Studied dose
    Dose not stated · oral · 34-44 weeksAs given in this study (human).

    Source sentences

    Summary
    Treatment satisfaction improved significantly during the study.
    2 context sentences
    Summary · context
    The multi-centre, prospective and non-interventional single-arm study enrolled 333 participants and followed them for 34-44 weeks.
    Summary · context
    Participants were treated as part of routine clinical practice and had not been previously treated with injectable glucose-lowering medication.
  7. 07HumanObservational studySafety outcome

    In adults with type 2 diabetes in UK routine care, no cases of severe hypoglycaemia were reported with oral semaglutide.

    In plain wordsIn adults with type 2 diabetes in routine UK care, no severe low blood sugar was reported with oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    No significant changeSevere hypoglycaemia
    Study

    n = 333

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated · oral · 34-44 weeksAs given in this study (human).

    Source sentences

    Summary
    No new safety concerns or cases of severe hypoglycaemia were reported.
    2 context sentences
    Summary · context
    The multi-centre, prospective and non-interventional single-arm study enrolled 333 participants and followed them for 34-44 weeks.
    Summary · context
    Participants were treated as part of routine clinical practice and had not been previously treated with injectable glucose-lowering medication.
  8. 08HumanObservational studySafety outcome

    In adults with type 2 diabetes in UK routine care, no new safety concerns were reported with oral semaglutide.

    In plain wordsIn adults with type 2 diabetes in routine UK care, no new safety problems were reported with oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    No significant changeNew safety concerns
    Study

    n = 333

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · oral · 34-44 weeksAs given in this study (human).

    Source sentences

    Summary
    No new safety concerns or cases of severe hypoglycaemia were reported.
    2 context sentences
    Summary · context
    The multi-centre, prospective and non-interventional single-arm study enrolled 333 participants and followed them for 34-44 weeks.
    Summary · context
    Participants were treated as part of routine clinical practice and had not been previously treated with injectable glucose-lowering medication.
  9. 09HumanObservational studyOther

    Of 333 participants on oral semaglutide, 299 completed the study and 227 were on treatment at end of study.

    In plain wordsOf 333 adults starting oral semaglutide in routine UK care, 227 were still taking it at the end of the study.

    Peptide
    Semaglutide
    Outcome
    Not applicableStudy completion and treatment persistence
    Study

    n = 333

    Outcome group
    Treatment adherence and retention · Whole body
    Studied dose
    Dose not stated · oral · 34-44 weeksAs given in this study (human).

    Source sentences

    Summary
    Of 333 participants, 299 completed the study and 227 were on treatment at EOS.
    2 context sentences
    Summary · context
    The multi-centre, prospective and non-interventional single-arm study enrolled 333 participants and followed them for 34-44 weeks.
    Summary · context
    Participants were treated as part of routine clinical practice and had not been previously treated with injectable glucose-lowering medication.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 1 ongoing · 1 completed · source ClinicalTrials.gov (opens in a new tab)

RecruitingPhase not statedNCT07621419

Study of Adult Patients Residing in Argentina Diagnosed With Type 2 Diabetes Treated With a New Formulation of Semaglutide, Both Oral and Subcutaneous, in a Real-world Setting at 3 Months, 6 Months, and 1 Year of Follow-up, Quantifying the Reduction in Glycated Hemoglobin

Hospital Italiano de Buenos Airesn = 1454 Aug 2025 to est. 31 Dec 2028

Diabetes Mellitus

Trial pageClinicalTrials.govUpdated 2 Jun 2026
CompletedPhase not statedNCT04862923

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in the United Kingdom, as Part of Local Clinical Practice

Novo Nordisk A/Sn = 33612 May 2021 to 31 Aug 2023

Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 24 Sept 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.